Published: 17 Feb. 2025(Updated: 17 Feb. 2025)
•36 min
•36 min read
•Denise Haslwanter, M Eugenia Dieterle, Anna Z Wec, Cecilia M O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C Garrett Rappazzo, Gorka Lasso a, Olivia Vergnolle, Ariel S Wirchnianski +A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
Cell culture
Researchers from Albert Einstein College of Medicine, Adimab LLC, and the U.S. Army Medical Research Institute of Infectious Diseases explored how combining neutralizing antibodies targeting different parts of the SARS-CoV-2 spike protein can help prevent escape mutants. Using the INFORS HT Multitron incubator shaker, they cultivated cells under controlled conditions to test antibody effectiveness. Their approach could strengthen antibody-based COVID-19 treatments by improving effectiveness and reducing resistance.